Gilead Sciences has received a subpoena from the Office of the Inspector General of the US Department of Health and Human Services requesting documents regarding the development, marketing and sales of Ranexa (ranolazine).

Ranexa has been approved by the US Food and Drug Administration as a treatment for chronic angina and was developed and originally commercialised by CV Therapeutics, a company acquired by Gilead in April 2009.

The biopharmaceutical company recently announced that it would be closing US facilities in Boulder and Westminster. The decision was reportedly prompted by the $1.4bn acquisition of CV Therapeutics earlier in 2009.